Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.89 |
| ▸ | CA1 | P00915 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184868 | 0.94 | LOXL2 (1.00) | LOXL2CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL210547 | 0.92 | LOXL2 (0.96) | LOXL2CA1CA2CA12CA9 | |
| Sulfuric Acid SCHEMBL2363547 | 0.87 | LOXL2 (0.86) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL28267713 | 0.86 | LOXL2 (0.83) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL7251467 | 0.86 | LOXL2 (0.83) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL12636516 | 0.86 | LOXL2 (0.83) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL2569067 | 0.85 | LOXL2 (0.71) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL10243318 | 0.85 | LOXL2 (0.63) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL10243185 | 0.85 | LOXL2 (0.63) | LOXL2CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL4464450 | 0.84 | LOXL2 (0.64) | LOXL2CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3787612-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2900633-A1 | ALPHA HYDROXY AMIDES | Merck Patent GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-1465613-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004020-A1 | HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | LOXL2 2955/4885CA1 4884/4885CA2 4751/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | LOXL2 1850/4885CA1 31/4885CA2 791/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | LOXL2 1782/4885CA1 4751/4885CA2 4527/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | LOXL2 3652/4885CA1 2480/4885CA2 2326/4885 |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, CD47, GLI1 | LOXL2 1937/4885CA1 527/4885CA2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.